<DOC>
	<DOC>NCT02186977</DOC>
	<brief_summary>A proof of concept (POC) study will be conducted in 44 volunteers that have been fully vaccinated against hepatitis B in the past (at least 5 years ago) to assess the safety and immunogenicity of intradermal vaccination with hepatitis B surface vaccine antigen using a newly developed intradermal injection device VAX-ID, compared to intramuscular and intradermal (Mantoux technique) injection.</brief_summary>
	<brief_title>Proof Of Concept : Immunogenicity and Safety of hepB Injection in the Dermis Using VAX-ID</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<criteria>healthy adults, checked anamnestically (based on medical history) at entry of the study 1835 years vaccination status: fully vaccinated against hepatitis B at least 5 years ago, with proof of vaccine response (to avoid nonresponse among the subjects). Subjects has to ask for a document of this proof at the service occupational medicine of the University of Antwerp. capable of understanding, reading and writing Dutch other vaccination(s) 4 weeks before study onset pregnancy and lactation (women will be questioned during anamnesis) plan to have other vaccination during the study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>immunogenicity</keyword>
	<keyword>safety</keyword>
	<keyword>proof of concept</keyword>
</DOC>